Miyake H - Search Results

1

Enhanced Sensitivity to NVP-BEZ235 by Inhibition of p62/SQSTM1 in Human Bladder Cancer KoTCC-1 Cells Both In Vitro and In Vivo.

Tamura K, Watanabe K, Matsushita Y, Watanabe H, Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H. Tamura K, et al. Among authors: miyake h. In Vivo. 2020 May-Jun;34(3):1001-1008. doi: 10.21873/invivo.11868. In Vivo. 2020. PMID: 32354885 Free PMC article.

2

Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in a human bladder cancer KoTCC-1 model.

Muramaki M, Miyake H, Hara I, Kawabata G, Kamidono S. Muramaki M, et al. Among authors: miyake h. J Urol. 2004 Oct;172(4 Pt 1):1485-9. doi: 10.1097/01.ju.0000133653.74536.43. J Urol. 2004. PMID: 15371876

3

Introduction of insulin-like growth factor binding protein-2 gene into human bladder cancer cells enhances their metastatic potential.

Miyake H, Hara I, Yamanaka K, Muramaki M, Gleave M, Eto H. Miyake H, et al. Oncol Rep. 2005 Feb;13(2):341-5. Oncol Rep. 2005. PMID: 15643522

4

Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.

Miyake H, Yamanaka K, Muramaki M, Hara I, Gleave ME. Miyake H, et al. Neoplasia. 2005 Feb;7(2):171-9. doi: 10.1593/neo.04478. Neoplasia. 2005. PMID: 15802022 Free PMC article.

5

Enhanced radiosensitivity by inhibition of the anti-apoptotic gene clusterin using antisense oligodeoxynucleotide in a human bladder cancer model.

Yamanaka K, Gleave M, Muramaki M, Hara I, Miyake H. Yamanaka K, et al. Among authors: miyake h. Oncol Rep. 2005 May;13(5):885-90. Oncol Rep. 2005. PMID: 15809754

6

Suppressed tumour growth and enhanced chemosensitivity by RNA interference targeting Aurora-A in the PC3 human prostate cancer model.

Kumano M, Miyake H, Terakawa T, Furukawa J, Fujisawa M. Kumano M, et al. Among authors: miyake h. BJU Int. 2010 Jul;106(1):121-7. doi: 10.1111/j.1464-410X.2009.09047.x. Epub 2009 Nov 12. BJU Int. 2010. PMID: 19912186

7

Small interfering RNA targeting heat shock protein 70 enhances chemosensitivity in human bladder cancer cells.

Behnsawy HM, Miyake H, Kusuda Y, Fujisawa M. Behnsawy HM, et al. Among authors: miyake h. Urol Oncol. 2013 Aug;31(6):843-8. doi: 10.1016/j.urolonc.2011.07.007. Epub 2011 Sep 1. Urol Oncol. 2013. PMID: 21889367

8

Significance of 4E-binding protein 1 as a therapeutic target for invasive urothelial carcinoma of the bladder.

Nishikawa M, Miyake H, Behnsawy HM, Fujisawa M. Nishikawa M, et al. Among authors: miyake h. Urol Oncol. 2015 Apr;33(4):166.e9-15. doi: 10.1016/j.urolonc.2014.12.006. Epub 2015 Jan 21. Urol Oncol. 2015. PMID: 25618298

9

Enhanced Sensitivity to Sunitinib by Inhibition of Akt1 Expression in Human Castration-resistant Prostate Cancer PC3 Cells Both In Vitro and In Vivo.

Nishikawa M, Miyake H, Fujisawa M. Nishikawa M, et al. Among authors: miyake h. Urology. 2015 May;85(5):1215.e1-1215.e7. doi: 10.1016/j.urology.2015.02.016. Urology. 2015. PMID: 25917740

10

Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model.

Nishikawa M, Miyake H, Gleave M, Fujisawa M. Nishikawa M, et al. Among authors: miyake h. Target Oncol. 2017 Feb;12(1):69-79. doi: 10.1007/s11523-016-0448-3. Target Oncol. 2017. PMID: 27526062

11

Comparative Assessment of Efficacies Between 2 Alternative Therapeutic Sequences With Novel Androgen Receptor-Axis-Targeted Agents in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.

Miyake H, Hara T, Tamura K, Sugiyama T, Furuse H, Ozono S, Fujisawa M. Miyake H, et al. Clin Genitourin Cancer. 2017 Aug;15(4):e591-e597. doi: 10.1016/j.clgc.2016.12.015. Epub 2016 Dec 22. Clin Genitourin Cancer. 2017. PMID: 28063845

12

Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide.

Miyake H, Hara T, Tamura K, Sugiyama T, Furuse H, Ozono S, Fujisawa M. Miyake H, et al. Urol Oncol. 2017 Jun;35(6):432-437. doi: 10.1016/j.urolonc.2017.01.006. Epub 2017 Feb 8. Urol Oncol. 2017. PMID: 28188090

13

Contralateral pneumothorax during retroperitoneal laparoscopic donor nephrectomy: A case report.

Matsushita Y, Miyake H, Motoyama D, Sugiyama T, Nagata M, Otsuka A, Furuse H, Ozono S. Matsushita Y, et al. Among authors: miyake h. Asian J Endosc Surg. 2017 May;10(2):202-204. doi: 10.1111/ases.12354. Epub 2017 Mar 17. Asian J Endosc Surg. 2017. PMID: 28303679

14

Comparison of Tyrosine Kinase Inhibitor Versus Mammalian Target of Rapamycin Inhibitor as Second-line Molecular-targeted Therapy for Patients with Poor-risk Metastatic Renal Cell Carcinoma.

Miyake H, Imai S, Tamura K, Sugiyama T, Furuse H, Ozono S, Fujisawa M. Miyake H, et al. Anticancer Res. 2017 Mar;37(3):1523-1528. doi: 10.21873/anticanres.11480. Anticancer Res. 2017. PMID: 28314328

15

No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer.

Miyake H, Sugiyama T, Aki R, Matsushita Y, Tamura K, Motoyama D, Ito T, Otsuka A. Miyake H, et al. Med Oncol. 2017 Aug;34(8):141. doi: 10.1007/s12032-017-1005-3. Epub 2017 Jul 17. Med Oncol. 2017. PMID: 28718092 Clinical Trial.

16

Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide.

Miyake H, Matsushita Y, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A. Miyake H, et al. Med Oncol. 2017 Nov 21;34(12):200. doi: 10.1007/s12032-017-1060-9. Med Oncol. 2017. PMID: 29164346

17

Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan.

Miyake H, Sugiyama T, Aki R, Matsushita Y, Tamura K, Motoyama D, Ito T, Otsuka A. Miyake H, et al. Clin Genitourin Cancer. 2018 Jun;16(3):219-225. doi: 10.1016/j.clgc.2017.11.007. Epub 2017 Dec 6. Clin Genitourin Cancer. 2018. PMID: 29274813

18

No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer.

Miyake H, Matsushita Y, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A. Miyake H, et al. Int J Clin Oncol. 2018 Jun;23(3):576-583. doi: 10.1007/s10147-017-1230-y. Epub 2017 Dec 23. Int J Clin Oncol. 2018. PMID: 29275450 Clinical Trial.

19

Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus.

Miyake H, Sugiyama T, Aki R, Matsushita Y, Tamura K, Motoyama D, Ito T, Otsuka A. Miyake H, et al. Int J Clin Oncol. 2018 Jun;23(3):553-558. doi: 10.1007/s10147-017-1232-9. Epub 2018 Jan 13. Int J Clin Oncol. 2018. PMID: 29332206

20

Isosamidin, an extract of Peucedanum japonicum, inhibits phenylephrine-mediated contractions of the human prostate in vitro.

Suzuki T, Otsuka A, Ito Y, Yamada S, Miyake H, Ozono S. Suzuki T, et al. Among authors: miyake h. Phytother Res. 2018 May;32(5):949-952. doi: 10.1002/ptr.6039. Epub 2018 Feb 1. Phytother Res. 2018. PMID: 29388272

21

Significance of Age in Japanese Patients Receiving Sunitinib as First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: Comparative Assessment of Efficacy and Safety between Patients Aged <75 and ≥75 Years.

Miyake H, Aki R, Matsushita Y, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A. Miyake H, et al. Anticancer Res. 2018 Jun;38(6):3593-3599. doi: 10.21873/anticanres.12633. Anticancer Res. 2018. PMID: 29848715

22

Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel.

Miyake H, Matsushita Y, Watanabe H, Tamura K, Suzuki T, Motoyama D, Ito T, Sugiyama T, Otsuka A. Miyake H, et al. Anticancer Res. 2018 Jul;38(7):4179-4185. doi: 10.21873/anticanres.12711. Anticancer Res. 2018. PMID: 29970547

23

Clinical characteristics of self-reported nocturia in patients with interstitial cystitis, and effects of bladder hydrodistention (with fulguration of Hunner lesions) on nocturia.

Otsuka A, Suzuki T, Aki R, Matsushita Y, Tamura K, Motoyama D, Ito T, Sugiyama T, Miyake H. Otsuka A, et al. Among authors: miyake h. Low Urin Tract Symptoms. 2019 Apr;11(2):O141-O146. doi: 10.1111/luts.12235. Epub 2018 Jul 16. Low Urin Tract Symptoms. 2019. PMID: 30010251

24

Significance of introduction of alternative dosing schedule for sunitinib during first-line treatment of patients with metastatic renal cell carcinoma.

Miyake H, Matsushita Y, Watanabe H, Tamura K, Suzuki T, Motoyama D, Ito T, Sugiyama T, Otsukav A. Miyake H, et al. Med Oncol. 2018 Aug 20;35(10):133. doi: 10.1007/s12032-018-1195-3. Med Oncol. 2018. PMID: 30128854

25

The Intrarenal Renin-angiotensin System Is Activated Immediately after Kidney Donation in Kidney Transplant Donors.

Ohashi N, Isobe S, Matsuyama T, Ishigaki S, Suzuki T, Tsuji T, Otsuka A, Kato A, Miyake H, Yasuda H. Ohashi N, et al. Among authors: miyake h. Intern Med. 2019 Mar 1;58(5):643-648. doi: 10.2169/internalmedicine.1756-18. Epub 2018 Oct 17. Intern Med. 2019. PMID: 30333423 Free PMC article.

26

Initial learning curve for robot-assisted partial nephrectomy performed by a single experienced robotic surgeon.

Motoyama D, Matsushita Y, Watanabe H, Tamura K, Suzuki T, Ito T, Sugiyama T, Otsuka A, Miyake H. Motoyama D, et al. Among authors: miyake h. Asian J Endosc Surg. 2020 Jan;13(1):59-64. doi: 10.1111/ases.12683. Epub 2019 Jan 28. Asian J Endosc Surg. 2020. PMID: 30689309

27

Clinical Outcomes of 42 Renal Cell Carcinoma Patients With Metastases Solely to the Lung Who Received Sorafenib as Second-line Systemic Therapy.

Miyake H, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A. Miyake H, et al. Anticancer Res. 2019 Feb;39(2):1067-1072. doi: 10.21873/anticanres.13214. Anticancer Res. 2019. PMID: 30711996

28

Improved perioperative outcomes by early unclamping prior to renorrhaphy compared with conventional clamping during robot-assisted partial nephrectomy: a propensity score matching analysis.

Motoyama D, Matsushita Y, Watanabe H, Tamura K, Ito T, Sugiyama T, Otsuka A, Miyake H. Motoyama D, et al. Among authors: miyake h. J Robot Surg. 2020 Feb;14(1):47-53. doi: 10.1007/s11701-019-00924-3. Epub 2019 Feb 2. J Robot Surg. 2020. PMID: 30712250

29

Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer.

Miyake H, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A. Miyake H, et al. Int J Clin Oncol. 2019 Jul;24(7):842-847. doi: 10.1007/s10147-019-01412-2. Epub 2019 Feb 9. Int J Clin Oncol. 2019. PMID: 30739263

30

Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer.

Miyake H, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A. Miyake H, et al. Anticancer Res. 2019 Mar;39(3):1391-1396. doi: 10.21873/anticanres.13253. Anticancer Res. 2019. PMID: 30842173

31

Discovery of lipid biomarkers correlated with disease progression in clear cell renal cell carcinoma using desorption electrospray ionization imaging mass spectrometry.

Tamura K, Horikawa M, Sato S, Miyake H, Setou M. Tamura K, et al. Among authors: miyake h. Oncotarget. 2019 Mar 1;10(18):1688-1703. doi: 10.18632/oncotarget.26706. eCollection 2019 Mar 1. Oncotarget. 2019. PMID: 30899441 Free PMC article.

32

Development of a Complete En-Bloc Technique with Direct Bladder Neck Incision: A Newly Modified Approach for Holmium Laser Enucleation of the Prostate.

Ito T, Tamura K, Otsuka A, Shinbo H, Takada S, Kurita Y, Miyake H. Ito T, et al. Among authors: miyake h. J Endourol. 2019 Oct;33(10):835-840. doi: 10.1089/end.2018.0773. Epub 2019 Jun 12. J Endourol. 2019. PMID: 31062613

33

Marked response to nivolumab combined with external radiation therapy for metastatic renal cell carcinoma: report of two cases.

Matsushita Y, Nakamura K, Furuse H, Ichinohe K, Miyake H. Matsushita Y, et al. Among authors: miyake h. Int Cancer Conf J. 2018 Nov 9;8(1):29-32. doi: 10.1007/s13691-018-0349-7. eCollection 2019 Jan. Int Cancer Conf J. 2018. PMID: 31149543 Free PMC article.

34

Optimal Timing of Cabazitaxel Introduction for Japanese Patients With Metastatic Castration-resistant Prostate Cancer.

Ito T, Kanao K, Takahara K, Ando R, Yasui T, Shiroki R, Sumitomo M, Miyake H. Ito T, et al. Among authors: miyake h. Anticancer Res. 2019 Jun;39(6):3089-3094. doi: 10.21873/anticanres.13444. Anticancer Res. 2019. PMID: 31177153

35

Prostate-specific antigen response patterns during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer.

Kanao K, Ito T, Takahara K, Ando R, Yasui T, Shiroki R, Miyake H, Sumitomo M. Kanao K, et al. Among authors: miyake h. Jpn J Clin Oncol. 2019 Dec 18;49(11):1043-1048. doi: 10.1093/jjco/hyz110. Jpn J Clin Oncol. 2019. PMID: 31369101

36

Feasibility of the ACL (albumin, C-reactive protein and lactate dehydrogenase) model as a novel prognostic tool in patients with metastatic renal cell carcinoma previously receiving first-line targeted therapy.

Tamura K, Matsushita Y, Watanabe H, Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H. Tamura K, et al. Among authors: miyake h. Urol Oncol. 2020 Jan;38(1):6.e9-6.e16. doi: 10.1016/j.urolonc.2019.07.013. Epub 2019 Aug 8. Urol Oncol. 2020. PMID: 31400935

37

Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model.

Hara T, Miyake H, Hinata N, Fujisawa M. Hara T, et al. Among authors: miyake h. Anticancer Res. 2019 Sep;39(9):4737-4742. doi: 10.21873/anticanres.13656. Anticancer Res. 2019. PMID: 31519573

38

Early Single-Center Experience with Robotic Partial Nephrectomy Using the da Vinci Xi: Comparative Assessment with Conventional Open Partial Nephrectomy.

Motoyama D, Aki R, Matsushita Y, Tamura K, Ito T, Sugiyama T, Otsuka A, Miyake H. Motoyama D, et al. Among authors: miyake h. Curr Urol. 2019 Sep;13(1):13-18. doi: 10.1159/000499300. Epub 2019 Sep 10. Curr Urol. 2019. PMID: 31579214 Free PMC article.

39

Significant impact of three-dimensional volumetry of perinephric fat on the console time during robot-assisted partial nephrectomy.

Motoyama D, Matsushita Y, Watanabe H, Tamura K, Ito T, Sugiyama T, Otsuka A, Miyake H. Motoyama D, et al. Among authors: miyake h. BMC Urol. 2019 Dec 12;19(1):132. doi: 10.1186/s12894-019-0567-0. BMC Urol. 2019. PMID: 31830961 Free PMC article.

40

Predictive factors for persistence of preoperative overactive bladder symptoms after transvaginal mesh surgery in women with pelvic organ prolapse.

Otsuka A, Watanabe K, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Miyake H. Otsuka A, et al. Among authors: miyake h. Low Urin Tract Symptoms. 2020 May;12(2):167-172. doi: 10.1111/luts.12299. Epub 2019 Dec 14. Low Urin Tract Symptoms. 2020. PMID: 31837207

41

Therapeutic Endoscopic Treatment Plus Maintenance Dimethyl Sulfoxide Therapy Prolongs Recurrence-Free Time in Patients With Hunner Type Interstitial Cystitis: A Pilot Study.

Otsuka A, Suzuki T, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Miyake H. Otsuka A, et al. Among authors: miyake h. Int Neurourol J. 2019 Dec;23(4):327-333. doi: 10.5213/inj.1938110.055. Epub 2019 Dec 31. Int Neurourol J. 2019. PMID: 31905280 Free PMC article.

42

Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney.

Watanabe K, Sugiyama T, Otsuka A, Miyake H. Watanabe K, et al. Among authors: miyake h. Int Cancer Conf J. 2019 Sep 28;9(1):32-35. doi: 10.1007/s13691-019-00389-z. eCollection 2020 Jan. Int Cancer Conf J. 2019. PMID: 31950015 Free PMC article.

43

Assessment of Factors Predicting Disease Progression in Japanese Patients With Non-Metastatic Castration-resistant Prostate Cancer.

Miyake H, Watanabe K, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A. Miyake H, et al. Anticancer Res. 2020 Feb;40(2):1101-1106. doi: 10.21873/anticanres.14049. Anticancer Res. 2020. PMID: 32014960

44

Corticosteroids alleviate adverse events associated with enzalutamide in patients with metastatic castration-resistant prostate cancer.

Tamura K, Matsushita Y, Watanabe H, Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H. Tamura K, et al. Among authors: miyake h. Mol Clin Oncol. 2020 May;12(5):495-500. doi: 10.3892/mco.2020.2013. Epub 2020 Mar 5. Mol Clin Oncol. 2020. PMID: 32257208 Free PMC article.

45

Second transurethral resection for high-risk non-muscle invasive bladder cancer patients: a propensity score matched analysis.

Matsushita Y, Watanabe K, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H. Matsushita Y, et al. Among authors: miyake h. Jpn J Clin Oncol. 2020 Jun 10;50(6):718-721. doi: 10.1093/jjco/hyaa041. Jpn J Clin Oncol. 2020. PMID: 32322885

46

Discontinuation of first-line molecular-targeted therapy and prognosis in patients with metastatic renal cell carcinoma: Impact of disease progression vs. adverse events.

Ando R, Takahara K, Ito T, Kanao K, Kobayashi I, Shiroki R, Sumitomo M, Miyake H, Yasui T. Ando R, et al. Among authors: miyake h. Urol Oncol. 2020 Dec;38(12):937.e19-937.e25. doi: 10.1016/j.urolonc.2020.06.023. Epub 2020 Jul 18. Urol Oncol. 2020. PMID: 32693975

47

Prognostic Stratification of the IMDC Intermediate Risk Group After Treatment With First-line Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma.

Takahara K, Ando R, Kanao K, Ito T, Miyake H, Sumitomo M, Yasui T, Shiroki R. Takahara K, et al. Among authors: miyake h. Anticancer Res. 2020 Aug;40(8):4395-4400. doi: 10.21873/anticanres.14443. Anticancer Res. 2020. PMID: 32727768

48

Radiation-induced sarcoma after radiation therapy for prostate adenocarcinoma.

Wakabayashi K, Konishi K, Komatsu T, Ishiba R, Ota N, Ito T, Aki R, Tsuchida T, Miyake H, Nakamura K. Wakabayashi K, et al. Among authors: miyake h. IJU Case Rep. 2019 Feb 24;2(2):98-101. doi: 10.1002/iju5.12052. eCollection 2019 Mar. IJU Case Rep. 2019. PMID: 32743384 Free PMC article.

49

Comprehensive assessment of oncological outcomes in 186 patients with high-risk non-muscle-invasive bladder cancer: A single institution retrospective study.

Matsushita Y, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H. Matsushita Y, et al. Among authors: miyake h. Mol Clin Oncol. 2020 Sep;13(3):16. doi: 10.3892/mco.2020.2086. Epub 2020 Jul 6. Mol Clin Oncol. 2020. PMID: 32754330 Free PMC article.

50

Kidney transplantation from a living donor with renal artery fibromuscular dysplasia: A case report on arterial grafting of the donor renal artery.

Matsushita Y, Motoyama D, Ito T, Sugiyama T, Otsuka A, Sano M, Inuzuka K, Miyake H. Matsushita Y, et al. Among authors: miyake h. IJU Case Rep. 2020 Jul 4;3(5):201-203. doi: 10.1002/iju5.12188. eCollection 2020 Sep. IJU Case Rep. 2020. PMID: 32914075 Free PMC article.

51

Development of novel ACN (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targeted therapy.

Tamura K, Ando R, Takahara K, Ito T, Kanao K, Yasui T, Shiroki R, Miyake H. Tamura K, et al. Among authors: miyake h. Urol Oncol. 2021 Jan;39(1):78.e1-78.e8. doi: 10.1016/j.urolonc.2020.08.029. Epub 2020 Sep 18. Urol Oncol. 2021. PMID: 32958444

52

Perioperative outcomes in patients undergoing robot-assisted partial nephrectomy: Comparative assessments between complex and non-complex renal tumors.

Motoyama D, Sato R, Watanabe K, Matsushita Y, Watanabe H, Matsumoto R, Ito T, Sugiyama T, Otsuka A, Miyake H. Motoyama D, et al. Among authors: miyake h. Asian J Endosc Surg. 2021 Jul;14(3):379-385. doi: 10.1111/ases.12872. Epub 2020 Oct 1. Asian J Endosc Surg. 2021. PMID: 33006270

53

Expression Profile of S100A2 and its Clinicopathological Significance in Renal Cell Carcinoma.

Sugiyama T, Ozono S, Miyake H. Sugiyama T, et al. Among authors: miyake h. Anticancer Res. 2020 Nov;40(11):6337-6343. doi: 10.21873/anticanres.14654. Anticancer Res. 2020. PMID: 33109571

54

Robot-Assisted Partial Nephrectomy for Patients with Multifocal Renal Tumors Arising in a Solitary Kidney: Report of Three Cases.

Miyake H, Motoyama D, Matsushita Y, Watanabe H, Ito T, Sugiyama T, Otsuka A. Miyake H, et al. J Endourol Case Rep. 2020 Dec 29;6(4):370-373. doi: 10.1089/cren.2020.0102. eCollection 2020. J Endourol Case Rep. 2020. PMID: 33457676 Free PMC article.

55

External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort.

Tamura K, Osawa T, Takeuchi A, Minami K, Nakai Y, Ueda K, Ozawa M, Uemura M, Sugimoto M, Ohba K, Suzuki T, Anai S, Shindo T, Kusakabe N, Komiyama M, Tanaka K, Yokomizo A, Kohei N, Shinohara N, Miyake H; Japanese Urological Oncology Group. Tamura K, et al. Among authors: miyake h. Jpn J Clin Oncol. 2021 Apr 30;51(5):810-818. doi: 10.1093/jjco/hyaa264. Jpn J Clin Oncol. 2021. PMID: 33479762

56

Renal allograft rejection after treatment with nivolumab in patients with metastatic renal cell carcinoma.

Ishikawa G, Sugiyama T, Ito T, Otsuka A, Miyake H. Ishikawa G, et al. Among authors: miyake h. Int Cancer Conf J. 2021 Jan 1;10(2):116-118. doi: 10.1007/s13691-020-00458-8. eCollection 2021 Apr. Int Cancer Conf J. 2021. PMID: 33786286 Free PMC article.

57

Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab.

Mizutani K, Ito T, Takahara K, Ando R, Ishihara T, Yasui T, Shiroki R, Miyake H, Koie T. Mizutani K, et al. Among authors: miyake h. Medicine (Baltimore). 2021 Apr 2;100(13):e25402. doi: 10.1097/MD.0000000000025402. Medicine (Baltimore). 2021. PMID: 33787647 Free PMC article.

58

Assessment of Blood Plasma Free-amino Acid Levels in Infertile Men.

Sugiyama T, Terada H, Miyake H. Sugiyama T, et al. Among authors: miyake h. In Vivo. 2021 May-Jun;35(3):1843-1847. doi: 10.21873/invivo.12446. In Vivo. 2021. PMID: 33910871 Free PMC article.

59

Pembrolizumab Versus Combined Chemotherapy With Gemcitabine and Paclitaxel: A Comparative Assessment of Clinical Outcomes in Patients With Platinum-refractory Advanced Urothelial Cancer.

Takemura A, Matsushita Y, Tamura K, Sugiyama T, Nagata M, Otsuka A, Miyake H. Takemura A, et al. Among authors: miyake h. In Vivo. 2021 May-Jun;35(3):1889-1894. doi: 10.21873/invivo.12453. In Vivo. 2021. PMID: 33910878 Free PMC article.

60

Watanabe H, Motoyama D, Sato R, Watanabe K, Matsushita Y, Ito T, Sugiyama T, Otsuka A, Miyake H. Watanabe H, et al. Among authors: miyake h. J Endourol. 2021 Nov;35(11):1644-1649. doi: 10.1089/end.2021.0254. J Endourol. 2021. PMID: 33971730

61

Impact of Bladder Neck Angle Measured by Postoperative Magnetic Resonance Imaging on Midterm Recovery of Urinary Continence in Prostate Cancer Patients Undergoing Robot-Assisted Radical Prostatectomy.

Ito T, Watanabe K, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Sugiyama T, Otsuka A, Miyake H. Ito T, et al. Among authors: miyake h. J Endourol. 2021 Nov;35(11):1610-1615. doi: 10.1089/end.2021.0071. Epub 2021 Sep 17. J Endourol. 2021. PMID: 34078137

62

Prognostic significance of third-line treatment for patients with metastatic castration-resistant prostate cancer: comparative assessments between cabazitaxel and other agents.

Miyake H, Sato R, Watanabe K, Matsushita Y, Watanabe H, Motoyama D, Ito T, Sugiyama T, Otsuka A. Miyake H, et al. Int J Clin Oncol. 2021 Sep;26(9):1745-1751. doi: 10.1007/s10147-021-01956-2. Epub 2021 Jul 13. Int J Clin Oncol. 2021. PMID: 34255227

63

Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells.

Watanabe H, Kawakami A, Sato R, Watanabe K, Matsushita Y, Miyake H. Watanabe H, et al. Among authors: miyake h. Anticancer Res. 2021 Aug;41(8):3753-3758. doi: 10.21873/anticanres.15167. Anticancer Res. 2021. PMID: 34281834

64

Prognostic assessments in patients with upper tract urothelial carcinoma undergoing radical nephroureterectomy and systematic regional lymph node dissection.

Sato R, Watanabe K, Matsushita Y, Watanabe H, Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H. Sato R, et al. Among authors: miyake h. Urologia. 2022 Aug;89(3):354-357. doi: 10.1177/03915603211034943. Epub 2021 Jul 29. Urologia. 2022. PMID: 34325582

65

Impacts of cachexia progression in addition to serum IgG and blood lymphocytes on serum nivolumab in advanced cancer patients.

Abe K, Shibata K, Naito T, Otsuka A, Karayama M, Maekawa M, Miyake H, Suda T, Kawakami J. Abe K, et al. Among authors: miyake h. Eur J Clin Pharmacol. 2022 Jan;78(1):77-87. doi: 10.1007/s00228-021-03199-6. Epub 2021 Aug 19. Eur J Clin Pharmacol. 2022. PMID: 34410448

66

Initial experience of robot-assisted radical nephrectomy in Japan: Single institutional study of 12 cases.

Miyake H, Motoyama D, Kawakami A, Sato R, Watanabe K, Matsushita Y, Watanabe H, Ito T, Sugiyama T, Otsuka A. Miyake H, et al. Asian J Endosc Surg. 2022 Jan;15(1):162-167. doi: 10.1111/ases.12986. Epub 2021 Sep 12. Asian J Endosc Surg. 2022. PMID: 34514709

67

Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world retrospective analysis.

Naiki T, Takahara K, Ito T, Nakane K, Sugiyama Y, Koie T, Shiroki R, Miyake H, Yasui T. Naiki T, et al. Among authors: miyake h. Int J Clin Oncol. 2022 Mar;27(3):592-601. doi: 10.1007/s10147-021-02071-y. Epub 2021 Nov 15. Int J Clin Oncol. 2022. PMID: 34779958

68

A DNA adductome analysis revealed a reduction in the global level of C5-hydroxymethyl-2'-deoxycytidine in the non-tumoral upper urinary tract mucosa of urothelial carcinoma patients.

Matsushita Y, Iwashita Y, Ohtsuka S, Ohnishi I, Yamashita T, Miyake H, Sugimura H. Matsushita Y, et al. Among authors: miyake h. Genes Environ. 2021 Dec 2;43(1):52. doi: 10.1186/s41021-021-00228-9. Genes Environ. 2021. PMID: 34852853 Free PMC article.

69

Useful predictors of progression-free survival for Japanese patients with LATITUDE-high-risk metastatic castration-sensitive prostate cancer who received upfront abiraterone acetate.

Takahara K, Naiki T, Ito T, Nakane K, Koie T, Yasui T, Miyake H, Shiroki R. Takahara K, et al. Among authors: miyake h. Int J Urol. 2022 Mar;29(3):229-234. doi: 10.1111/iju.14754. Epub 2021 Dec 4. Int J Urol. 2022. PMID: 34863085 Free PMC article.

70

Assessment of prognostic factors in previously treated Japanese patients with metastatic renal cell carcinoma who received nivolumab: An observational multi-institute study.

Ito T, Mizutani K, Takahara K, Ando R, Yasui T, Shiroki R, Koie T, Miyake H. Ito T, et al. Among authors: miyake h. Mol Clin Oncol. 2022 Jan;16(1):17. doi: 10.3892/mco.2021.2446. Epub 2021 Nov 21. Mol Clin Oncol. 2022. PMID: 34881037 Free PMC article.

71

Feasibility of interaortocaval clamping for renal artery during robot-assisted right partial nephrectomy: A propensity score-matching analysis.

Motoyama D, Kawakami A, Sato R, Watanabe K, Matsushita Y, Watanabe H, Ito T, Sugiyama T, Otsuka A, Miyake H. Motoyama D, et al. Among authors: miyake h. Asian J Endosc Surg. 2022 Jul;15(3):531-538. doi: 10.1111/ases.13041. Epub 2022 Feb 9. Asian J Endosc Surg. 2022. PMID: 35138037

72

Limited impact of erectile function on health-related quality of life in Japanese men undergoing robot-assisted radical prostatectomy.

Tamura K, Matsushita Y, Watanabe H, Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H. Tamura K, et al. Among authors: miyake h. Int J Urol. 2022 Sep;29(9):956-961. doi: 10.1111/iju.14826. Epub 2022 Feb 17. Int J Urol. 2022. PMID: 35176812

73

Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study).

Kobayashi K, Matsuyama H, Kawai T, Ikeda A, Miyake M, Nishimoto K, Matsushita Y, Komura K, Abe T, Kume H, Nishiyama H, Fujimoto K, Oyama M, Miyake H, Inoue K, Mitsui T, Kawakita M, Ohyama C, Mizokami A, Kuroiwa H. Kobayashi K, et al. Among authors: miyake h, miyake m. Int J Urol. 2022 Jul;29(7):632-638. doi: 10.1111/iju.14854. Epub 2022 Mar 15. Int J Urol. 2022. PMID: 35293022 Free PMC article.

74

Significance of 5-Aminolevulinic Acid-mediated Photodynamic Diagnosis Following Standard Transurethral Resection in Non-muscle Invasive Bladder Cancer.

Watanabe K, Tamura K, Matsushita Y, Watanabe H, Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H. Watanabe K, et al. Among authors: miyake h. Cancer Diagn Progn. 2021 Jul 3;1(3):201-205. doi: 10.21873/cdp.10027. eCollection 2021 Jul-Aug. Cancer Diagn Progn. 2021. PMID: 35399308 Free PMC article.

75

Significant impact of a history of prior or concomitant upper urinary tract cancer on the recurrence and progression of non-muscle invasive bladder cancer.

Matsushita Y, Kawakami A, Sato R, Watanabe K, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H. Matsushita Y, et al. Among authors: miyake h. Jpn J Clin Oncol. 2022 Aug 5;52(8):944-949. doi: 10.1093/jjco/hyac068. Jpn J Clin Oncol. 2022. PMID: 35462401

76

Robot-assisted radical nephrectomy and inferior vena cava tumor thrombectomy: Initial experience in Japan.

Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H. Motoyama D, et al. Among authors: miyake h. IJU Case Rep. 2022 Jan 25;5(3):145-148. doi: 10.1002/iju5.12419. eCollection 2022 May. IJU Case Rep. 2022. PMID: 35509774 Free PMC article.

77

Summary of the Clinical Practice Guidelines for Penile Cancer 2021 by the Japanese Urological Association.

Yamaguchi T, Sugiyama Y, Tanaka T, Kimura T, Yumura Y, Nakano M, Sugiyama T, Miura N, Goya M, Yamamoto A, Takahashi S, Miura Y, Tsuzuki T, Masumori N, Nishiyama H, Yao M, Koie T, Miyake H, Saika T, Saito S, Akimoto T, Tamada T, Ando Y, Takahashi S, Suzuki T, Hinotsu S, Kamba T. Yamaguchi T, et al. Among authors: miyake h. Int J Urol. 2022 Aug;29(8):780-792. doi: 10.1111/iju.14924. Epub 2022 May 28. Int J Urol. 2022. PMID: 35643932 Review.

78

Comparison of perioperative outcomes among patients with exophytic, mesophytic, and endophytic renal tumors undergoing robot-assisted partial nephrectomy.

Motoyama D, Ito T, Sugiyama T, Otsuka A, Miyake H. Motoyama D, et al. Among authors: miyake h. Int J Urol. 2022 Sep;29(9):1026-1030. doi: 10.1111/iju.14946. Epub 2022 Jun 6. Int J Urol. 2022. PMID: 35669994

79

Development of a Simple and Objective Prognostication Model for Patients with Advanced Solid Malignant Tumors Treated with Immune Checkpoint Inhibitors: A Pan-Cancer Analysis.

Sano A, Inoue Y, Kikuchi H, Fukuchi K, Funai K, Imai A, Matsushita Y, Tamura K, Kitagawa M, Miyake H. Sano A, et al. Among authors: miyake h. Target Oncol. 2022 Sep;17(5):583-589. doi: 10.1007/s11523-022-00911-z. Epub 2022 Sep 12. Target Oncol. 2022. PMID: 36094602

80

Predictive factors of de novo overactive bladder in clinically localized prostate cancer patients after robot-assisted radical prostatectomy.

Watanabe K, Otsuka A, Sano A, Sato R, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Miyake H. Watanabe K, et al. Among authors: miyake h. Int J Urol. 2023 Jan;30(1):57-61. doi: 10.1111/iju.15060. Epub 2022 Dec 13. Int J Urol. 2023. PMID: 36513615

81

Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab.

Sato R, Inamoto T, Matsushita Y, Takemura A, Uchimoto T, Sano A, Tanaka H, Ishikawa G, Watanabe K, Watanabe H, Tamura K, Motoyama D, Sugiyama T, Otsuka A, Harada KI, Azuma H, Miyake H. Sato R, et al. Among authors: miyake h. Int J Urol. 2023 Sep;30(9):730-736. doi: 10.1111/iju.15133. Epub 2022 Dec 27. Int J Urol. 2023. PMID: 36575640

82

Validation of the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non-muscle invasive bladder cancer: A multi-institutional collaborative study.

Miyamoto T, Miyake M, Nakahama T, Nishimura N, Onishi K, Iida K, Yonemori M, Enokida H, Nakagawa M, Matsumoto H, Matsuyama H, Matsushita Y, Miyake H, Fujii T, Shimada K, Baba S, Kinjyo M, Shimokama T, Okumura K, Fujimoto K; Nishinihon Uro-oncology Extensive Collaboration group. Miyamoto T, et al. Among authors: miyake h, miyake m. Int J Urol. 2023 May;30(5):473-481. doi: 10.1111/iju.15162. Epub 2023 Feb 14. Int J Urol. 2023. PMID: 36788781

83

Initial Experience of Robot-Assisted Partial Nephrectomy Using Hinotori Surgical Robot System: Single Institutional Prospective Assessment of Perioperative Outcomes in 30 Cases.

Miyake H, Motoyama D, Matsushita Y, Watanabe H, Tamura K, Otsuka A, Fujisawa M. Miyake H, et al. J Endourol. 2023 May;37(5):531-534. doi: 10.1089/end.2022.0775. Epub 2023 Mar 28. J Endourol. 2023. PMID: 36800894

84

Additional oncological benefit of photodynamic diagnosis with blue light cystoscopy in transurethral resection for primary non-muscle-invasive bladder cancer: A comparative study from experienced institutes.

Miyake M, Nishimura N, Nakahama T, Nishimoto K, Oyama M, Matsushita Y, Miyake H, Fukuhara H, Inoue K, Kobayashi K, Matsumoto H, Matsuyama H, Fujii T, Hirao Y, Fujimoto K. Miyake M, et al. Among authors: miyake h. BJUI Compass. 2023 Jan 13;4(3):305-313. doi: 10.1002/bco2.215. eCollection 2023 May. BJUI Compass. 2023. PMID: 37025476 Free PMC article.

85

Trends in the Use of Second-Generation Androgen Receptor Axis Inhibitors for Metastatic Hormone-Sensitive Prostate Cancer and Clinical Factors Predicting Biological Recurrence.

Nakane K, Watanabe H, Naiki T, Takahara K, Yasui T, Miyake H, Shiroki R, Koie T. Nakane K, et al. Among authors: miyake h. Diagnostics (Basel). 2023 May 8;13(9):1661. doi: 10.3390/diagnostics13091661. Diagnostics (Basel). 2023. PMID: 37175052 Free PMC article.

86

Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan.

Harada KI, Sato R, Bando Y, Sano A, Matsushita Y, Tamura K, Terakawa T, Furukawa J, Fujimoto N, Fujisawa M, Miyake H. Harada KI, et al. Among authors: miyake h. Int J Urol. 2023 Sep;30(9):772-777. doi: 10.1111/iju.15230. Epub 2023 Jun 22. Int J Urol. 2023. PMID: 37345413

87

Assessments of therapeutic effects according to timings for combined therapy with axitinib and immune check point inhibitor in a mouse renal cell carcinoma model.

Watanabe H, Matsushita Y, Tamura K, Motoyama D, Sugiyama T, Otsuka A, Miyake H. Watanabe H, et al. Among authors: miyake h. Sci Rep. 2023 Jul 13;13(1):11361. doi: 10.1038/s41598-023-37857-9. Sci Rep. 2023. PMID: 37443122 Free PMC article.

88

Perioperative outcomes of robot-assisted partial nephrectomy using hinotori versus da Vinci surgical robot system: a propensity score-matched analysis.

Motoyama D, Matsushita Y, Watanabe H, Tamura K, Otsuka A, Fujisawa M, Miyake H. Motoyama D, et al. Among authors: miyake h. J Robot Surg. 2023 Oct;17(5):2435-2440. doi: 10.1007/s11701-023-01614-x. Epub 2023 Jul 18. J Robot Surg. 2023. PMID: 37462888

89

Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.

Nishimura N, Miyake M, Nakahama T, Miyamoto T, Nishimoto K, Oyama M, Matsushita Y, Miyake H, Fukuhara H, Inoue K, Kobayashi K, Matsumoto H, Matsuyama H, Fujii T, Hirao Y, Fujimoto K. Nishimura N, et al. Among authors: miyake h, miyake m. Int J Urol. 2023 Dec;30(12):1112-1119. doi: 10.1111/iju.15283. Epub 2023 Aug 22. Int J Urol. 2023. PMID: 37605814

90

Robot-assisted radical nephrectomy using novel surgical robot platform, hinotori: Report of initial series of 13 cases.

Motoyama D, Matsushita Y, Watanabe H, Tamura K, Otsuka A, Fujisawa M, Miyake H. Motoyama D, et al. Among authors: miyake h. Int J Urol. 2023 Dec;30(12):1175-1179. doi: 10.1111/iju.15292. Epub 2023 Sep 1. Int J Urol. 2023. PMID: 37654155

91

Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study.

Sazuka T, Matsushita Y, Sato H, Osawa T, Hinata N, Hatakeyama S, Numakura K, Ueda K, Kimura T, Takahashi M, Tanaka H, Kawasaki Y, Kurahashi T, Kato T, Fujita K, Miyake M, Kojima T, Kitamura H, Miyake H, Ichikawa T. Sazuka T, et al. Among authors: miyake h, miyake m. Sci Rep. 2023 Nov 23;13(1):20629. doi: 10.1038/s41598-023-48087-4. Sci Rep. 2023. PMID: 37996622 Free PMC article.

92

Comparative assessment of disease recurrence after transurethral resection of non-muscle-invasive bladder cancer with and without a photodynamic diagnosis using 5-aminolevulinic acid: a propensity score-matching analysis.

Matsushita Y, Miyake M, Nishimura N, Nishimoto K, Fukuhara H, Kobayashi K, Oyama M, Inoue K, Matsuyama H, Fujimoto K, Miyake H. Matsushita Y, et al. Among authors: miyake h, miyake m. Int J Clin Oncol. 2024 Feb;29(2):205-212. doi: 10.1007/s10147-023-02447-2. Epub 2023 Dec 19. Int J Clin Oncol. 2024. PMID: 38112832

93

Robot-assisted radical nephroureterectomy for upper urinary tract tumor: initial experience with the use of novel surgical robot system, hinotori.

Motoyama D, Matsushita Y, Watanabe H, Tamura K, Otsuka A, Fujisawa M, Miyake H. Motoyama D, et al. Among authors: miyake h. Transl Cancer Res. 2023 Dec 31;12(12):3522-3529. doi: 10.21037/tcr-23-853. Epub 2023 Dec 21. Transl Cancer Res. 2023. PMID: 38197081 Free PMC article.

94

Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy.

Matsushita Y, Kojima T, Osawa T, Sazuka T, Hatakeyama S, Goto K, Numakura K, Yamana K, Kandori S, Fujita K, Ueda K, Tanaka H, Tomida R, Kurahashi T, Bando Y, Nishiyama N, Kimura T, Yamashita S, Kitamura H, Miyake H; Japanese Urological Oncology Group. Matsushita Y, et al. Among authors: miyake h. Int J Urol. 2024 May;31(5):526-533. doi: 10.1111/iju.15396. Epub 2024 Jan 19. Int J Urol. 2024. PMID: 38240169

95

Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan.

Hara T, Matsushita Y, Harada K, Fujimoto N, Fujisawa M, Miyake H. Hara T, et al. Among authors: miyake h. Int J Urol. 2024 Feb 29. doi: 10.1111/iju.15435. Online ahead of print. Int J Urol. 2024. PMID: 38424707 No abstract available.

96

Robot-assisted radical nephrectomy and inferior vena cava tumor thrombectomy using the novel surgical robot platform, hinotori: Initial experience with two cases.

Motoyama D, Matsushita Y, Watanabe H, Tamura K, Otsuka A, Fujisawa M, Miyake H. Motoyama D, et al. Among authors: miyake h. IJU Case Rep. 2023 Nov 21;7(2):96-99. doi: 10.1002/iju5.12673. eCollection 2024 Mar. IJU Case Rep. 2023. PMID: 38440702 Free PMC article.

97

Differences in oncological benefits from second transurethral resection between white-light initial surgery and photodynamic diagnosis-guided initial surgery for primary high-risk non-muscle invasive bladder cancer.

Miyake M, Nishimura N, Nakahama T, Nishimoto K, Oyama M, Matsushita Y, Miyake H, Fukuhara H, Inoue K, Kobayashi K, Matsuyama H, Fujii T, Hirao Y, Fujimoto K. Miyake M, et al. Among authors: miyake h. Int J Urol. 2024 Apr 30. doi: 10.1111/iju.15474. Online ahead of print. Int J Urol. 2024. PMID: 38687165

98

Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Comparative Analysis of Retrospective Real-world Data.

Tomida R, Takahashi M, Matsushita Y, Kojima T, Yamana K, Kandori S, Bando Y, Nishiyama N, Yamashita S, Taniguchi H, Monji K, Ishiyama R, Tatarano S, Masui K, Matsuda A, Kaneko T, Motoshima T, Shiraishi Y, Kira S, Murashima T, Hara H, Matsumura M, Kitamura H, Miyake H, Furukawa J; Japanese Urological Oncology Group. Tomida R, et al. Among authors: miyake h. Clin Genitourin Cancer. 2024 Apr 15:102094. doi: 10.1016/j.clgc.2024.102094. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 38714434

99

Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression.

Miyake H, Hara I, Kamidono S, Gleave ME, Eto H. Miyake H, et al. Oncol Rep. 2003 Mar-Apr;10(2):469-73. Oncol Rep. 2003. PMID: 12579291

100

Introduction of midkine gene into human bladder cancer cells enhances their malignant phenotype but increases their sensitivity to antiangiogenic therapy.

Muramaki M, Miyake H, Hara I, Kamidono S. Muramaki M, et al. Among authors: miyake h. Clin Cancer Res. 2003 Nov 1;9(14):5152-60. Clin Cancer Res. 2003. PMID: 14613994

101

Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer kotcc-1 cells.

Miyake H, Eto H, Hara I, So A, Li D, Gleave ME. Miyake H, et al. J Urol. 2004 Jun;171(6 Pt 1):2477-81. doi: 10.1097/01.ju.0000118382.89456.f7. J Urol. 2004. PMID: 15126879

102

Antitumor effect of simultaneous transfer of interleukin-12 and interleukin-18 genes and its mechanism in a mouse bladder cancer model.

Hikosaka S, Hara I, Miyake H, Hara S, Kamidono S. Hikosaka S, et al. Among authors: miyake h. Int J Urol. 2004 Aug;11(8):647-52. doi: 10.1111/j.1442-2042.2004.00855.x. Int J Urol. 2004. PMID: 15285756 Free article.

103

Antisense oligodeoxynucleotide therapy for bladder cancer: recent advances and future prospects.

Miyake H, Hara I, Fujisaw M, Gleave ME. Miyake H, et al. Expert Rev Anticancer Ther. 2005 Dec;5(6):1001-9. doi: 10.1586/14737140.5.6.1001. Expert Rev Anticancer Ther. 2005. PMID: 16336091 Review.

104

Significance of radical cystectomy for bladder cancer in patients over 80 years old.

Yamanaka K, Miyake H, Hara I, Inoue TA, Fujisawa M. Yamanaka K, et al. Among authors: miyake h. Int Urol Nephrol. 2007;39(1):209-14. doi: 10.1007/s11255-006-9122-5. Epub 2006 Nov 3. Int Urol Nephrol. 2007. PMID: 17082907

105

Upper urinary tract recurrence following radical cystectomy for bladder cancer.

Furukawa J, Miyake H, Hara I, Takenaka A, Fujisawa M. Furukawa J, et al. Among authors: miyake h. Int J Urol. 2007 Jun;14(6):496-9. doi: 10.1111/j.1442-2042.2007.01776.x. Int J Urol. 2007. PMID: 17593092

106

Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: correlation with intravesical recurrence following transurethral resection.

Behnsawy HM, Miyake H, Abdalla MA, Sayed MA, Ahmed Ael-F, Fujisawa M. Behnsawy HM, et al. Among authors: miyake h. Urol Oncol. 2011 Sep-Oct;29(5):495-501. doi: 10.1016/j.urolonc.2009.08.002. Epub 2009 Nov 13. Urol Oncol. 2011. PMID: 19914103

107

The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells.

Terakawa T, Miyake H, Kumano M, Sakai I, Fujisawa M. Terakawa T, et al. Among authors: miyake h. Oncol Rep. 2010 Nov;24(5):1395-9. doi: 10.3892/or_00000998. Oncol Rep. 2010. PMID: 20878136

108

Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model.

Sakai I, Miyake H, Terakawa T, Fujisawa M. Sakai I, et al. Among authors: miyake h. Cancer Sci. 2011 Apr;102(4):769-75. doi: 10.1111/j.1349-7006.2011.01854.x. Epub 2011 Feb 11. Cancer Sci. 2011. PMID: 21214673 Free article.

109

Growth inhibition and enhanced chemosensitivity induced by down-regulation of Aurora-A in human renal cell carcinoma Caki-2 cells using short hairpin RNA.

Terakawa T, Miyake H, Kumano M, Fujisawa M. Terakawa T, et al. Among authors: miyake h. Oncol Lett. 2011 Jul;2(4):713-717. doi: 10.3892/ol.2011.295. Epub 2011 Apr 28. Oncol Lett. 2011. PMID: 22848254 Free PMC article.

110

Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.

Sakai I, Miyake H, Fujisawa M. Sakai I, et al. Among authors: miyake h. BJU Int. 2013 Jul;112(2):E211-20. doi: 10.1111/j.1464-410X.2012.11655.x. Epub 2013 Jan 10. BJU Int. 2013. PMID: 23305097

111

Sequential use of mammalian target of rapamycin inhibitors in patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitors.

Kumano M, Miyake H, Harada K, Fujisawa M. Kumano M, et al. Among authors: miyake h. Med Oncol. 2013 Dec;30(4):745. doi: 10.1007/s12032-013-0745-y. Epub 2013 Oct 13. Med Oncol. 2013. PMID: 24122255

112

Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.

Nishikawa M, Miyake H, Harada K, Fujisawa M. Nishikawa M, et al. Among authors: miyake h. Urol Oncol. 2014 Jan;32(1):49.e15-21. doi: 10.1016/j.urolonc.2013.07.014. Epub 2013 Nov 13. Urol Oncol. 2014. PMID: 24239474

113

Limited significance of activated Akt-mammalian target of rapamycin signaling pathway in prostate cancer progression.

Ko YH, Miyake H, Behnsawy HM, Cheon J, Fujisawa M. Ko YH, et al. Among authors: miyake h. Urol Int. 2014;93(2):146-51. doi: 10.1159/000356262. Epub 2014 Feb 20. Urol Int. 2014. PMID: 24556942

114

Assessment of health-related quality of life in Japanese patients with metastatic renal cell carcinoma during treatment with tyrosine kinase inhibitors.

Miyake H, Harada K, Inoue TA, Fujisawa M. Miyake H, et al. Med Oncol. 2014 Sep;31(9):190. doi: 10.1007/s12032-014-0190-6. Epub 2014 Aug 22. Med Oncol. 2014. PMID: 25146670

115

Expression profile of epithelial-mesenchymal transition markers in non-muscle-invasive urothelial carcinoma of the bladder: correlation with intravesical recurrence following transurethral resection.

Liu B, Miyake H, Nishikawa M, Fujisawa M. Liu B, et al. Among authors: miyake h. Urol Oncol. 2015 Mar;33(3):110.e11-8. doi: 10.1016/j.urolonc.2014.08.012. Epub 2014 Sep 26. Urol Oncol. 2015. PMID: 25262382

116

Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo.

Tei H, Miyake H, Fujisawa M. Tei H, et al. Among authors: miyake h. Hum Cell. 2015 Jul;28(3):114-21. doi: 10.1007/s13577-015-0112-8. Epub 2015 Apr 11. Hum Cell. 2015. PMID: 25862630

117

No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma.

Miyazaki A, Miyake H, Harada K, Fujisawa M. Miyazaki A, et al. Among authors: miyake h. Anticancer Res. 2015 May;35(5):3067-73. Anticancer Res. 2015. PMID: 25964597

118

UNC-51-like kinase 1 expression in radical nephrectomy specimens as a predicting factor of progression-free survival in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors.

Nishikawa M, Miyake H, Bing L, Fujisawa M. Nishikawa M, et al. Among authors: miyake h. Urol Oncol. 2015 Dec;33(12):506.e1-7. doi: 10.1016/j.urolonc.2015.07.013. Epub 2015 Aug 20. Urol Oncol. 2015. PMID: 26299883

119

Cancer-specific and net overall survival in older patients with de novo metastatic prostate cancer initially treated with androgen deprivation therapy.

Narita S, Terada N, Nomura K, Sakamoto S, Hatakeyama S, Kato T, Matsui Y, Inokuchi J, Yokomizo A, Tabata KI, Shiota M, Kimura T, Kojima T, Inoue T, Mizowaki T, Sugimoto M, Kitamura H, Kamoto T, Nishiyama H, Habuchi T; Japanese Urological Oncology Group. Narita S, et al. Int J Urol. 2022 Oct;29(10):1147-1154. doi: 10.1111/iju.14938. Epub 2022 May 25. Int J Urol. 2022. PMID: 35613936

120

Over expression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer.

Miyake H, Eto H, Arakawa S, Kamidono S, Hara I. Miyake H, et al. J Urol. 2002 Mar;167(3):1282-7. J Urol. 2002. PMID: 11832714

121

Introducing the clusterin gene into human renal cell carcinoma cells enhances their metastatic potential.

Miyake H, Gleave ME, Arakawa S, Kamidono S, Hara I. Miyake H, et al. J Urol. 2002 May;167(5):2203-8. J Urol. 2002. PMID: 11956479

122

Over expression of CD44V8-10 in human bladder cancer cells decreases their interaction with hyaluronic acid and potentiates their malignant progression.

Muramaki M, Miyake H, Kamidono S, Hara I. Muramaki M, et al. Among authors: miyake h. J Urol. 2004 Jan;171(1):426-30. doi: 10.1097/01.ju.0000093446.54115.b6. J Urol. 2004. PMID: 14665947

123

Significance of renal function in changes in acid-base metabolism after orthotopic bladder replacement: colon neobladder compared with ileal neobladder.

Miyake H, Hara S, Eto H, Arakawa S, Kamidono S, Hara I. Miyake H, et al. Int J Urol. 2004 Feb;11(2):83-7. doi: 10.1111/j.1442-2042.2004.00749.x. Int J Urol. 2004. PMID: 14706011 Free article.

124

Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen.

Miyake H, Hara I, Gleave ME, Eto H. Miyake H, et al. Prostate. 2004 Dec 1;61(4):318-23. doi: 10.1002/pros.20087. Prostate. 2004. PMID: 15389725

125

Limited significance of routine excretory urography in the follow-up of patients with superficial bladder cancer after transurethral resection.

Miyake H, Hara I, Yamanaka K, Inoue TA, Fujisawa M. Miyake H, et al. BJU Int. 2006 Apr;97(4):720-3. doi: 10.1111/j.1464-410X.2006.06032.x. BJU Int. 2006. PMID: 16536761

126

The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer.

Miyake H, Hara I, Fujisawa M, Gleave ME. Miyake H, et al. Expert Opin Investig Drugs. 2006 May;15(5):507-17. doi: 10.1517/13543784.15.5.507. Expert Opin Investig Drugs. 2006. PMID: 16634689 Review.

127

Persistent expression of Aurora-A after neoadjuvant hormonal therapy as a predictor of a poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.

Furukawa J, Miyake H, Takenaka A, Hara I, Fujisawa M. Furukawa J, et al. Among authors: miyake h. BJU Int. 2007 Aug;100(2):310-4. doi: 10.1111/j.1464-410X.2007.06982.x. Epub 2007 May 19. BJU Int. 2007. PMID: 17511772

128

Clinical outcome of radical cystectomy for patients with pT4 bladder cancer.

Furukawa J, Miyake H, Hara I, Takenaka A, Fujisawa M. Furukawa J, et al. Among authors: miyake h. Int J Urol. 2008 Jan;15(1):58-61. doi: 10.1111/j.1442-2042.2007.01916.x. Int J Urol. 2008. PMID: 18184174

129

Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.

Muramaki M, Miyake H, Kurahashi T, Takenaka A, Inoue TA, Fujisawa M. Muramaki M, et al. Among authors: miyake h. Int J Urol. 2008 Apr;15(4):314-8. doi: 10.1111/j.1442-2042.2008.02000.x. Int J Urol. 2008. PMID: 18380818

130

Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.

Miyake H, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M. Miyake H, et al. Urol Oncol. 2010 Mar-Apr;28(2):145-51. doi: 10.1016/j.urolonc.2008.08.001. Epub 2008 Oct 10. Urol Oncol. 2010. PMID: 18848789

131

Modulation of the microenvironment by growth factors regulates the in vivo growth of skeletal myoblasts.

Yanagiuchi A, Miyake H, Nomi M, Takenaka A, Fujisawa M. Yanagiuchi A, et al. Among authors: miyake h. BJU Int. 2009 Jun;103(11):1569-73. doi: 10.1111/j.1464-410x.2008.08318.x. BJU Int. 2009. PMID: 19504751

132

Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection.

Muramaki M, Miyake H, Terakawa T, Kumano M, Sakai I, Fujisawa M. Muramaki M, et al. Among authors: miyake h. Urol Oncol. 2012 Mar-Apr;30(2):161-6. doi: 10.1016/j.urolonc.2010.01.005. Epub 2010 May 6. Urol Oncol. 2012. PMID: 20451421

133

Metastatic collecting duct carcinoma of the kidney responded to sunitinib.

Miyake H, Haraguchi T, Takenaka A, Fujisawa M. Miyake H, et al. Int J Clin Oncol. 2011 Apr;16(2):153-5. doi: 10.1007/s10147-010-0116-z. Epub 2010 Aug 5. Int J Clin Oncol. 2011. PMID: 20686910

134

Expression of integrin proteins in non-muscle-invasive bladder cancer: significance of intravesical recurrence after transurethral resection.

Behnsawy HM, Miyake H, Abdalla MA, Sayed MA, Ahmed Ael-F, Fujisawa M. Behnsawy HM, et al. Among authors: miyake h. BJU Int. 2011 Jan;107(2):240-6. doi: 10.1111/j.1464-410X.2010.09534.x. Epub 2010 Aug 24. BJU Int. 2011. PMID: 20735384

135

β4-integrin-mediated cytotoxic activity of AexU in human prostate cancer PC3 cells.

Kumano M, Miyake H, Abolghait SK, Behnsawy HM, Fujisawa M. Kumano M, et al. Among authors: miyake h. Oncol Lett. 2013 Nov;6(5):1482-1486. doi: 10.3892/ol.2013.1542. Epub 2013 Aug 23. Oncol Lett. 2013. PMID: 24179545 Free PMC article.

136

Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors.

Nishikawa M, Miyake H, Harada K, Fujisawa M. Nishikawa M, et al. Among authors: miyake h. Med Oncol. 2014 Jan;31(1):792. doi: 10.1007/s12032-013-0792-4. Epub 2013 Dec 4. Med Oncol. 2014. PMID: 24307346

137

Sonic hedgehog and androgen signaling in tumor and stromal compartments drives epithelial-mesenchymal transition in prostate cancer.

Yamamichi F, Shigemura K, Behnsawy HM, Meligy FY, Huang WC, Li X, Yamanaka K, Hanioka K, Miyake H, Tanaka K, Kawabata M, Shirakawa T, Fujisawa M. Yamamichi F, et al. Among authors: miyake h. Scand J Urol. 2014 Dec;48(6):523-32. doi: 10.3109/21681805.2014.898336. Epub 2014 Mar 19. Scand J Urol. 2014. PMID: 25356787

138

Acceleration of Proteinuria without Significant Impact on Renal Function and Its Protection by Angiotensin II Receptor Blocker in Rats Treated with Axitinib.

Imai S, Miyake H, Fujisawa M. Imai S, et al. Among authors: miyake h. Target Oncol. 2016 Jun;11(3):309-15. doi: 10.1007/s11523-015-0393-6. Target Oncol. 2016. PMID: 26423685 Clinical Trial.

139

Changes in Renal Function of Patients with Metastatic Renal Cell Carcinoma During Treatment with Molecular-Targeted Agents.

Miyake H, Muramaki M, Imai S, Harada K, Fujisawa M. Miyake H, et al. Target Oncol. 2016 Jun;11(3):329-35. doi: 10.1007/s11523-015-0395-4. Target Oncol. 2016. PMID: 26507837

140

Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan.

Miyake H, Harada KI, Ozono S, Fujisawa M. Miyake H, et al. Clin Genitourin Cancer. 2017 Feb;15(1):122-128. doi: 10.1016/j.clgc.2016.06.019. Epub 2016 Jul 5. Clin Genitourin Cancer. 2017. PMID: 27473522

141

Characterization of urocortin as an anti-apoptotic protein in experimental ischemia-reperfusion model of the rat testis.

Sumii K, Miyake H, Enatsu N, Chiba K, Fujisawa M. Sumii K, et al. Among authors: miyake h. Biochem Biophys Res Commun. 2016 Oct 14;479(2):387-392. doi: 10.1016/j.bbrc.2016.09.091. Epub 2016 Sep 20. Biochem Biophys Res Commun. 2016. PMID: 27659706

142

Expression pattern of immune checkpoint-associated molecules in radical nephrectomy specimens as a prognosticator in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.

Hara T, Miyake H, Fujisawa M. Hara T, et al. Among authors: miyake h. Urol Oncol. 2017 Jun;35(6):363-369. doi: 10.1016/j.urolonc.2017.01.002. Epub 2017 Feb 4. Urol Oncol. 2017. PMID: 28169111

143

Expression profile of mammalian target of rapamycin-related proteins in graft biopsy specimens: Significance for predicting interstitial fibrosis after kidney transplantation.

Ogawa S, Ishimura T, Miyake H, Fujisawa M. Ogawa S, et al. Among authors: miyake h. Int J Urol. 2017 Mar;24(3):223-229. doi: 10.1111/iju.13287. Epub 2017 Feb 7. Int J Urol. 2017. PMID: 28173612

144

Association of Expression Levels or Activation Status of STAT3 with Treatment Outcomes of Sunitinib in Patients with Renal Cell Carcinoma.

Yamamoto K, Hara T, Nakagawa T, Hirai M, Miyake H, Fujisawa M, Yano I. Yamamoto K, et al. Among authors: miyake h. Target Oncol. 2018 Jun;13(3):371-378. doi: 10.1007/s11523-018-0563-4. Target Oncol. 2018. PMID: 29633072

145

Risk for intravesical recurrence of bladder cancer stratified by the results on two consecutive UroVysion fluorescence in situ hybridization tests: a prospective follow-up study in Japan.

Ikeda A, Kojima T, Kawai K, Hinotsu S, Keino N, Shiga K, Miyake H, Miyata Y, Enomoto Y, Shimizu F, Anai S, Matsuyama H, Suzuki C, Kanimoto Y, Shigeta K, Naito S, Akaza H, Nishiyama H. Ikeda A, et al. Among authors: miyake h. Int J Clin Oncol. 2020 Jun;25(6):1163-1169. doi: 10.1007/s10147-020-01634-9. Epub 2020 Mar 3. Int J Clin Oncol. 2020. PMID: 32125546 Free PMC article.

146

Impact of carcinoma in situ on the outcome of intravesical Bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer: a comparative analysis of large real-world data.

Tomida R, Miyake M, Minato R, Sawada Y, Matsumura M, Iida K, Hori S, Fukui S, Ohyama C, Miyake H, Hongo F, Taoka R, Kobayashi T, Kojima T, Matsui Y, Nishiyama N, Kitamura H, Nishiyama H, Fujimoto K, Hashine K; Japanese Urological Oncology Group. Tomida R, et al. Among authors: miyake h, miyake m. Int J Clin Oncol. 2022 May;27(5):958-968. doi: 10.1007/s10147-022-02127-7. Epub 2022 Feb 10. Int J Clin Oncol. 2022. PMID: 35142962

147

Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence.

Miyake H, Gleave M, Kamidono S, Hara I. Miyake H, et al. Urology. 2002 Jan;59(1):150-4. doi: 10.1016/s0090-4295(01)01484-4. Urology. 2002. PMID: 11796313

148

Clinical outcome of bacillus Calmette-Guérin perfusion therapy for carcinoma in situ of the upper urinary tract.

Miyake H, Eto H, Hara S, Okada H, Kamidono S, Hara I. Miyake H, et al. Int J Urol. 2002 Dec;9(12):677-80. doi: 10.1046/j.1442-2042.2002.00551.x. Int J Urol. 2002. PMID: 12492951 Free article.

149

Global analysis of gene expression profiles in ileum in a rat bladder augmentation model using cDNA microarrays.

Miyake H, Hara S, Eto H, Kamidono S, Hara I. Miyake H, et al. Int J Urol. 2004 Nov;11(11):1009-12. doi: 10.1111/j.1442-2042.2004.00942.x. Int J Urol. 2004. PMID: 15509206 Free article.

150

Prognostic significance of insulin-like growth factor (IGF) binding protein-2 to IGF-binding protein-3 ratio in patients undergoing radical cystectomy for invasive transitional cell carcinoma of the bladder.

Miyake H, Hara I, Yamanaka K, Muramaki M, Eto H. Miyake H, et al. BJU Int. 2005 May;95(7):987-91. doi: 10.1111/j.1464-410X.2005.05453.x. BJU Int. 2005. PMID: 15839919

151

Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic.

Miyake H, Hara I, Gleave ME. Miyake H, et al. Int J Urol. 2005 Sep;12(9):785-94. doi: 10.1111/j.1442-2042.2005.01173.x. Int J Urol. 2005. PMID: 16201973 Review.

152

Clinicopathological features of recurrence after radical cystectomy for patients with transitional cell carcinoma of the bladder.

Harada K, Sakai I, Kurahashi T, Muramaki M, Yamanaka K, Hara I, Eto H, Miyake H. Harada K, et al. Among authors: miyake h. Int Urol Nephrol. 2006;38(1):49-55. doi: 10.1007/s11255-005-2944-8. Int Urol Nephrol. 2006. PMID: 16502052

153

Significance of Aurora-A expression in renal cell carcinoma.

Kurahashi T, Miyake H, Hara I, Fujisawa M. Kurahashi T, et al. Among authors: miyake h. Urol Oncol. 2007 Mar-Apr;25(2):128-33. doi: 10.1016/j.urolonc.2006.06.001. Urol Oncol. 2007. PMID: 17349527

154

Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.

Terakawa T, Miyake H, Kusuda Y, Fujisawa M. Terakawa T, et al. Among authors: miyake h. Urol Oncol. 2013 May;31(4):493-8. doi: 10.1016/j.urolonc.2011.02.012. Epub 2011 Apr 7. Urol Oncol. 2013. PMID: 21478036

155

Significance of docetaxel-based chemotherapy as treatment for metastatic castration-resistant prostate cancer in Japanese men over 75 years old.

Miyake H, Sakai I, Harada K, Muramaki M, Fujisawa M. Miyake H, et al. Int Urol Nephrol. 2012 Dec;44(6):1697-703. doi: 10.1007/s11255-012-0223-z. Epub 2012 Jun 24. Int Urol Nephrol. 2012. PMID: 22729777

156

Efficacy and safety of temsirolimus in Japanese patients with metastatic renal cell carcinoma on hemodialysis.

Miyake H, Harada K, Kusuda Y, Fujisawa M. Miyake H, et al. Int J Clin Oncol. 2013 Dec;18(6):1054-9. doi: 10.1007/s10147-012-0492-7. Epub 2012 Nov 1. Int J Clin Oncol. 2013. PMID: 23114786

157

[High-dose chemotherapy for advanced testicular germ cell tumors].

Miyake H, Fujisawa M. Miyake H, et al. Hinyokika Kiyo. 2012 Dec;58(12):731-5. Hinyokika Kiyo. 2012. PMID: 23328175 Free article. Japanese.

158

Expression profile of CD44s, CD44v6, and CD44v10 in localized prostate cancer: effect on prognostic outcomes following radical prostatectomy.

Tei H, Miyake H, Harada K, Fujisawa M. Tei H, et al. Among authors: miyake h. Urol Oncol. 2014 Jul;32(5):694-700. doi: 10.1016/j.urolonc.2013.12.002. Epub 2014 Jan 24. Urol Oncol. 2014. PMID: 24468288

159

Significance of random bladder biopsies in non-muscle invasive bladder cancer.

Kumano M, Miyake H, Nakano Y, Fujisawa M. Kumano M, et al. Among authors: miyake h. Curr Urol. 2013 Nov;7(2):57-61. doi: 10.1159/000356249. Epub 2013 Oct 30. Curr Urol. 2013. PMID: 24917759 Free PMC article.

160

Non-significant impact of proteinuria on renal function in Japanese patients with metastatic renal cell carcinoma treated with axitinib.

Miyake H, Harada K, Imai S, Miyazaki A, Fujisawa M. Miyake H, et al. Int J Clin Oncol. 2015 Aug;20(4):796-801. doi: 10.1007/s10147-014-0770-7. Epub 2014 Nov 26. Int J Clin Oncol. 2015. PMID: 25424248

161

Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan.

Miyake H, Miyazaki A, Imai S, Harada K, Fujisawa M. Miyake H, et al. Target Oncol. 2016 Apr;11(2):175-82. doi: 10.1007/s11523-015-0385-6. Target Oncol. 2016. PMID: 26341668

162

Prognostic Significance of Early Tumor Shrinkage Under Second-Line Targeted Therapy for Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Study in Japan.

Miyake H, Harada K, Ozono S, Fujisawa M. Miyake H, et al. Mol Diagn Ther. 2016 Aug;20(4):385-92. doi: 10.1007/s40291-016-0206-3. Mol Diagn Ther. 2016. PMID: 27178184

163

Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma.

Miyake H, Harada K, Ozono S, Fujisawa M. Miyake H, et al. Med Oncol. 2016 Aug;33(8):95. doi: 10.1007/s12032-016-0813-1. Epub 2016 Jul 21. Med Oncol. 2016. PMID: 27444960

164

GLI2 expression levels in radical nephrectomy specimens as a predictor of disease progression in patients with metastatic clear cell renal cell carcinoma following treatment with sunitinib.

Furukawa J, Miyake H, Fujisawa M. Furukawa J, et al. Among authors: miyake h. Mol Clin Oncol. 2016 Sep;5(3):186-192. doi: 10.3892/mco.2016.950. Epub 2016 Jul 6. Mol Clin Oncol. 2016. PMID: 27602218 Free PMC article.

165

Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis.

Tomita Y, Yamamoto Y, Tsuchiya N, Kanayama H, Eto M, Miyake H, Powles T, Yoshida M, Koide Y, Umeyama Y, di Pietro A, Uemura H. Tomita Y, et al. Among authors: miyake h. Int J Clin Oncol. 2022 Feb;27(2):383-395. doi: 10.1007/s10147-021-02067-8. Epub 2022 Jan 1. Int J Clin Oncol. 2022. PMID: 34973108 Free PMC article. Clinical Trial.

166

Comprehensive assessments of immuno-oncology drug-based combination therapies as first-line treatment for advanced renal cell carcinoma.

Harada KI, Miyake H, Furukawa J, Fujimoto N, Fujisawa M. Harada KI, et al. Among authors: miyake h. Int J Urol. 2022 Aug;29(8):816-822. doi: 10.1111/iju.14922. Epub 2022 May 30. Int J Urol. 2022. PMID: 35636920 Review.

167

Optimal timing of radical cystectomy for patients with invasive transitional cell carcinoma of the bladder.

Hara I, Miyake H, Hara S, Gotoh A, Okada H, Arakawa S, Kamidono S. Hara I, et al. Among authors: miyake h. Jpn J Clin Oncol. 2002 Jan;32(1):14-8. doi: 10.1093/jjco/hyf002. Jpn J Clin Oncol. 2002. PMID: 11932357

168

Prognostic significance of vascular invasion in patients with bladder cancer who underwent radical cystectomy.

Harada K, Sakai I, Hara I, Eto H, Miyake H. Harada K, et al. Among authors: miyake h. Int J Urol. 2005 Mar;12(3):250-5. doi: 10.1111/j.1442-2042.2005.01037.x. Int J Urol. 2005. PMID: 15828951

169

Urinary levels of vascular endothelial growth factor in patients with prostate cancer as a predictor of disease progression.

Miyake H, Muramaki M, Kurahashi T, Yamanaka K, Hara I. Miyake H, et al. Anticancer Res. 2005 Sep-Oct;25(5):3645-9. Anticancer Res. 2005. PMID: 16101195 Free article.

170

Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.

Miyake H, Hara I, Eto H. Miyake H, et al. BJU Int. 2005 Oct;96(6):791-5. doi: 10.1111/j.1464-410X.2005.05766.x. BJU Int. 2005. PMID: 16153202

171

Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.

Miyake H, Muramaki M, Kurahashi T, Yamanaka K, Hara I, Fujisawa M. Miyake H, et al. Anticancer Res. 2006 Mar-Apr;26(2B):1583-7. Anticancer Res. 2006. PMID: 16619575 Free article. Clinical Trial.

172

Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation.

Miyake H, Kurahashi T, Yamanaka K, Kondo Y, Muramaki M, Takenaka A, Inoue TA, Fujisawa M. Miyake H, et al. Urol Oncol. 2010 Sep-Oct;28(5):515-9. doi: 10.1016/j.urolonc.2009.08.011. Epub 2009 Nov 13. Urol Oncol. 2010. PMID: 19914105

173

[Resistance to tyrosine kinase inhibitors in renal cell carcinoma].

Miyake H, Fujisawa M. Miyake H, et al. Nihon Rinsho. 2012 Nov;70 Suppl 8:331-5. Nihon Rinsho. 2012. PMID: 23513861 Japanese. No abstract available.

174

Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib.

Miyake H, Nishikawa M, Tei H, Furukawa J, Harada K, Fujisawa M. Miyake H, et al. Urol Oncol. 2014 Jul;32(5):584-8. doi: 10.1016/j.urolonc.2014.01.016. Epub 2014 Mar 26. Urol Oncol. 2014. PMID: 24680659

175

Editorial comment to Salvage combined chemotherapy with paclitaxel, ifosfamide and nedaplatin for patients with advanced germ cell tumors.

Miyake H, Fujisawa M. Miyake H, et al. Int J Urol. 2015 Mar;22(3):293. doi: 10.1111/iju.12676. Epub 2014 Nov 25. Int J Urol. 2015. PMID: 25422037 No abstract available.

176

Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib.

Miyake H, Harada K, Miyazaki A, Fujisawa M. Miyake H, et al. Med Oncol. 2015 Mar;32(3):78. doi: 10.1007/s12032-015-0528-8. Epub 2015 Feb 20. Med Oncol. 2015. PMID: 25698532 Clinical Trial.

177

Performance status as a significant prognostic predictor in patients with urothelial carcinoma of the bladder who underwent radical cystectomy.

Hinata N, Miyake H, Miyazaki A, Nishikawa M, Tei H, Fujisawa M. Hinata N, et al. Among authors: miyake h. Int J Urol. 2015 Aug;22(8):742-6. doi: 10.1111/iju.12804. Epub 2015 May 18. Int J Urol. 2015. PMID: 25988857

178

Irinotecan and nedaplatin as salvage therapy for patients with advanced germ cell tumors following intensive treatment with cisplatin-based combination chemotherapies.

Nishikawa M, Miyake H, Fujisawa M. Nishikawa M, et al. Among authors: miyake h. Int J Clin Oncol. 2016 Feb;21(1):162-7. doi: 10.1007/s10147-015-0861-0. Epub 2015 Jun 28. Int J Clin Oncol. 2016. PMID: 26123313

179

Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.

Miyake H, Imai S, Harada K, Fujisawa M. Miyake H, et al. Clin Genitourin Cancer. 2016 Feb;14(1):e19-24. doi: 10.1016/j.clgc.2015.08.002. Epub 2015 Aug 15. Clin Genitourin Cancer. 2016. PMID: 26382221

180

Comparative Assessment of Clinical Outcomes Between Abiraterone Acetate and Enzalutamide in Patients With Docetaxel-Naive Metastatic Castration-Resistant Prostate Cancer: Experience in Real-World Clinical Practice in Japan.

Miyake H, Hara T, Terakawa T, Ozono S, Fujisawa M. Miyake H, et al. Clin Genitourin Cancer. 2017 Apr;15(2):313-319. doi: 10.1016/j.clgc.2016.06.010. Epub 2016 Jun 23. Clin Genitourin Cancer. 2017. PMID: 27424256

181

The Inverse Association between the Baseline Renal Function and Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Molecular-Targeted Agents.

Miyake H, Imai S, Ozono S, Fujisawa M. Miyake H, et al. Curr Urol. 2017 Nov;10(4):186-192. doi: 10.1159/000447179. Epub 2017 Oct 22. Curr Urol. 2017. PMID: 29234261 Free PMC article.

182

[Ⅰ. Are There Any Changes in the Epidemiological Trends in Renal Cell Carcinoma in Japan ?].

Miyake H. Miyake H. Gan To Kagaku Ryoho. 2019 Jan;46(1):36-39. Gan To Kagaku Ryoho. 2019. PMID: 30765639 Japanese. No abstract available.

183

Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin.

Muramaki M, So A, Hayashi N, Sowery R, Miyake H, Fujisawa M, Gleave ME. Muramaki M, et al. Among authors: miyake h. BJU Int. 2009 Feb;103(3):384-90. doi: 10.1111/j.1464-410X.2008.08098.x. Epub 2008 Oct 24. BJU Int. 2009. PMID: 19007378

184

Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.

Miyake H, Sakai I, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M. Miyake H, et al. Int J Urol. 2009 May;16(5):465-71. doi: 10.1111/j.1442-2042.2009.02262.x. Int J Urol. 2009. PMID: 19467119

185

Orthotopic sigmoid neobladder after radical cystectomy: assessment of complications, functional outcomes and quality of life in 82 Japanese patients.

Miyake H, Furukawa J, Muramaki M, Takenaka A, Fujisawa M. Miyake H, et al. BJU Int. 2010 Aug;106(3):412-6. doi: 10.1111/j.1464-410X.2009.09006.x. Epub 2009 Nov 3. BJU Int. 2010. PMID: 19888974

186

Orthotopic bladder substitution following radical cystectomy in women: comparative study between sigmoid and ileal neobladders.

Miyake H, Furukawa J, Muramaki M, Takenaka A, Fujisawa M. Miyake H, et al. Urol Oncol. 2012 Jan-Feb;30(1):38-43. doi: 10.1016/j.urolonc.2009.11.006. Epub 2010 Jan 6. Urol Oncol. 2012. PMID: 20056456

187

Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.

Kusuda Y, Miyake H, Behnsawy HM, Fukuhara T, Inoue TA, Fujisawa M. Kusuda Y, et al. Among authors: miyake h. Urol Oncol. 2013 Jan;31(1):42-50. doi: 10.1016/j.urolonc.2010.09.008. Epub 2011 Mar 10. Urol Oncol. 2013. PMID: 21396851

188

Expression profile of E-cadherin and N-cadherin in urothelial carcinoma of the upper urinary tract is associated with disease recurrence in patients undergoing nephroureterectomy.

Muramaki M, Miyake H, Terakawa T, Kusuda Y, Fujisawa M. Muramaki M, et al. Among authors: miyake h. Urology. 2011 Dec;78(6):1443.e7-12. doi: 10.1016/j.urology.2011.07.1388. Epub 2011 Sep 15. Urology. 2011. PMID: 21924460

189

Orthotopic sigmoid vs. ileal neobladders in Japanese patients: a comparative assessment of complications, functional outcomes, and quality of life.

Miyake H, Furukawa J, Sakai I, Muramaki M, Yamashita M, Inoue TA, Fujisawa M. Miyake H, et al. Urol Oncol. 2013 Oct;31(7):1155-60. doi: 10.1016/j.urolonc.2011.11.015. Epub 2011 Dec 6. Urol Oncol. 2013. PMID: 22153716

190

Miyake H, Harada K, Kusuda Y, Fujisawa M. Miyake H, et al. Int J Clin Oncol. 2013 Apr;18(2):220-5. doi: 10.1007/s10147-011-0364-6. Epub 2011 Dec 27. Int J Clin Oncol. 2013. PMID: 22198800

191

Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy.

Harada K, Miyake H, Kusuda Y, Fujisawa M. Harada K, et al. Among authors: miyake h. BJU Int. 2012 Dec;110(11 Pt C):E1131-7. doi: 10.1111/j.1464-410X.2012.11297.x. Epub 2012 Jun 19. BJU Int. 2012. PMID: 22712620

192

Possible role of sonic hedgehog and epithelial-mesenchymal transition in renal cell cancer progression.

Behnsawy HM, Shigemura K, Meligy FY, Yamamichi F, Yamashita M, Haung WC, Li X, Miyake H, Tanaka K, Kawabata M, Shirakawa T, Fujisawa M. Behnsawy HM, et al. Among authors: miyake h. Korean J Urol. 2013 Aug;54(8):547-54. doi: 10.4111/kju.2013.54.8.547. Epub 2013 Aug 7. Korean J Urol. 2013. PMID: 23956832 Free PMC article.

193

Assessment of efficacy, safety and quality of life of 55 patients with metastatic renal cell carcinoma treated with temsirolimus: a single-center experience in Japan.

Miyake H, Harada K, Kumano M, Fujisawa M. Miyake H, et al. Int J Clin Oncol. 2014 Aug;19(4):679-85. doi: 10.1007/s10147-013-0617-7. Epub 2013 Sep 10. Int J Clin Oncol. 2014. PMID: 24019183

194

Clinical outcome of paclitaxel and carboplatin as second-line chemotherapy for advanced urothelial carcinoma resistant to first-line therapy with gemcitabine and cisplatin.

Terakawa T, Miyake H, Yokoyama N, Miyazaki A, Tanaka H, Inoue T, Fujisawa M. Terakawa T, et al. Among authors: miyake h. Urol Int. 2014;92(2):180-5. doi: 10.1159/000354149. Epub 2013 Nov 13. Urol Int. 2014. PMID: 24246751

195

Expression Profile of Autophagy-related Markers in Localized Prostate Cancer: Correlation With Biochemical Recurrence After Radical Prostatectomy.

Liu B, Miyake H, Nishikawa M, Tei H, Fujisawa M. Liu B, et al. Among authors: miyake h. Urology. 2015 Jun;85(6):1424-30. doi: 10.1016/j.urology.2015.03.006. Epub 2015 Apr 14. Urology. 2015. PMID: 25881865

196

Impact of Prior Use of an Androgen Receptor-Axis-Targeted (ARAT) Agent With or Without Subsequent Taxane Therapy on the Efficacy of Another ARAT Agent in Patients With Metastatic Castration-Resistant Prostate Cancer.

Miyake H, Hara T, Ozono S, Fujisawa M. Miyake H, et al. Clin Genitourin Cancer. 2017 Apr;15(2):e217-e222. doi: 10.1016/j.clgc.2016.07.005. Epub 2016 Jul 21. Clin Genitourin Cancer. 2017. PMID: 27522450

197

Role of the serotonergic system in urethral continence reflexes during sneezing in rats.

Suzuki T, Shimizu T, Kwon J, Takaoka E, Yoshikawa S, Sumino Y, Kitta T, Miyazato M, Miyake H, Yoshimura N. Suzuki T, et al. Among authors: miyake h. Am J Physiol Renal Physiol. 2018 Jul 1;315(1):F79-F85. doi: 10.1152/ajprenal.00614.2017. Epub 2018 Feb 14. Am J Physiol Renal Physiol. 2018. PMID: 29442547 Free PMC article.

198

Cytoreductive nephrectomy following treatment with anti-vascular endothelial growth factor-targeted agents: is it surgically safe?

Miyake H. Miyake H. Ann Transl Med. 2019 Dec;7(Suppl 8):S347. doi: 10.21037/atm.2019.09.106. Ann Transl Med. 2019. PMID: 32016065 Free PMC article. No abstract available.

199

Treatment strategies and outcomes in a long-term registry study of patients with high-risk metastatic hormone-naïve prostate cancer in Japan: An interim analysis of the J-ROCK study.

Uemura H, Matsumoto R, Mizokami A, Miyake H, Uemura H, Matsuyama H, Nakamura K, Saito K, Kawakita M, Takeshita H, Koroki Y, Ono S, Murota M, Ito M, Kamoto T, Fujimoto K. Uemura H, et al. Among authors: miyake h. Int J Urol. 2022 Sep;29(9):1061-1070. doi: 10.1111/iju.14993. Epub 2022 Aug 26. Int J Urol. 2022. PMID: 36018236 Free PMC article.

200

Detection of micrometastases in pelvic lymph nodes in patients undergoing radical cystectomy for locally invasive bladder cancer by real-time reverse transcriptase-PCR for cytokeratin 19 and uroplakin II.

Kurahashi T, Hara I, Oka N, Kamidono S, Eto H, Miyake H. Kurahashi T, et al. Among authors: miyake h. Clin Cancer Res. 2005 May 15;11(10):3773-7. doi: 10.1158/1078-0432.CCR-04-2297. Clin Cancer Res. 2005. PMID: 15897575 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,148 results

Search Page